<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670382</url>
  </required_header>
  <id_info>
    <org_study_id>2845</org_study_id>
    <nct_id>NCT02670382</nct_id>
  </id_info>
  <brief_title>Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids</brief_title>
  <official_title>Role of EPA and DHA in Fish Oil on Inflammation and Lipoprotein Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to provide critical information regarding both common and
      distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, crossover study of the effects of EPA
      and DHA on inflammation and lipid metabolism in 24 men and women with metabolic syndrome. The
      study will characterize the effects of EPA alone and DHA alone, relative to each other and to
      placebo, on plasma biomarkers of inflammation, inflammatory cell activation and gene
      expression, and plasma lipid and lipoprotein levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>interleukin-6 (IL-6)</measure>
    <time_frame>10 weeks</time_frame>
    <description>plasma levels in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-alpha)</measure>
    <time_frame>10 weeks</time_frame>
    <description>plasma levels in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>10 weeks</time_frame>
    <description>plasma levels in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>high density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>10 weeks</time_frame>
    <description>plasma levels in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>triglycerides</measure>
    <time_frame>10 weeks</time_frame>
    <description>plasma levels in mg/dL</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>EPA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA</intervention_name>
    <description>10 week supplementation</description>
    <arm_group_label>EPA intervention</arm_group_label>
    <other_name>eicosapentaenoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA</intervention_name>
    <description>10 week supplementation</description>
    <arm_group_label>DHA intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sunflower oil</intervention_name>
    <description>10 week supplementation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  fasting plasma TG levels between 150 and 500 mg/dL

          -  C-reactive protein (CRP) levels ≥2 µg/mL

          -  at least one of the following criteria for the definition of metabolic syndrome:

               -  abdominal obesity (waist circumference &gt;40 inches in men and &gt;35 inches in
                  women),

               -  hypertension (blood pressure ≥130/≥85 mmHg or use of anti-hypertensive
                  medications), and

               -  fasting glucose ≥110 mg/dL.

        Exclusion criteria:

          -  high-fish diets (&gt;2 fish meals/week)

          -  taking fish oil supplements or supplements containing EPA or DHA

          -  allergy to sardines

          -  allergy to sunflower oil

          -  regular use of anti-inflammatory medications (NSAID, COX inhibitors, corticosteroids)

          -  anticoagulant therapy

          -  alcohol consumption &gt;7 drinks/week

          -  uncontrolled thyroid dysfunction

          -  insulin-dependent type 2 diabetes mellitus

          -  kidney or liver disease

          -  smoking

          -  alterations in coagulation

          -  use of lipid altering medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefania Lamon-Fava, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefania Lamon-Fava, PhD</last_name>
    <phone>617-556-3105</phone>
    <email>stefania.lamon-fava@tufts.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jean Mayer Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Lamon-Fava, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Stefania Lamon-Fava, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Stefania lamon-Fava</investigator_full_name>
    <investigator_title>Scientist I, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The objective of this study is to provide critical information regarding both common and distinctive roles of the omega-3 fatty acids EPA and DHA in systemic inflammation and lipid metabolism.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

